CHARISE BATTEL: Open Payments
NPI 1316368814 · BRISTOL, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,928 in 102 payments from 24 companies in 2025. Trend: 2023 $125 · 2024 $1,154 · 2025 $1,928
Food & beverage: $1,928
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 28 | $336 |
| Novo Nordisk Inc | 11 | $286 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $257 |
| AstraZeneca Pharmaceuticals LP | 11 | $215 |
| Exact Sciences Corporation | 5 | $110 |
| GlaxoSmithKline, LLC. | 6 | $102 |
| Novartis Pharmaceuticals Corporation | 4 | $80 |
| PFIZER INC. | 4 | $67 |
| Vanda Pharmaceuticals Inc. | 3 | $55 |
| Regeneron Healthcare Solutions, Inc. | 2 | $53 |
Products named: CAPLYTA, Wegovy, QULIPTA, Cologuard Collection Kit, BREZTRI, TRELEGY ELLIPTA, FARXIGA, VRAYLAR.
Industry payments across VA — which companies pay providers there.
